# What to Expect When Switching to a Biosimilar: A US Healthcare Professional’s Perspective

## TL;DR

This paper discusses the patient experience when switching from a reference product to a biosimilar treatment for inflammatory bowel disease from the perspective of healthcare professionals in the US.

## Contribution

The paper provides insights from a physician assistant and pharmacist on managing patient expectations during biosimilar switches.

## Key findings

- Healthcare professionals highlight the importance of patient communication during biosimilar transitions.
- Switching to biosimilars is becoming more common in inflammatory bowel disease treatment.

## Abstract

As biosimilars become more available, many patients with inflammatory bowel disease may experience having their treatment switched from a reference product to a biosimilar. In this communication, a physician assistant and a pharmacist discuss the patient experience when switching to a biosimilar.

Graphical Abstract